Ambitious AB Science Gets Masitinib Win For Severe Asthma
Drug In Trials For Seven Indications
Executive SummaryPlagued by concerns on the integrity of data and compliance issues with its clinical practices, the French firm still believes masitinib could be effective for ALS, multiple sclerosis, cancers, asthma and even Alzheimer's.
You may also be interested in...
A retrospective analysis of new drugs evaluated by the European Medicines Agency since 2010 shows that a lack of, or major deficiencies in, human mass balance studies is still a concern in regulatory submissions.
The European Medicines Agency’s CHMP is deciding the fate of several new drugs at its April meeting, which is taking place this week.
The Italian firm has some talking to do with the US FDA before it can unblind Phase III data on sarizotan, its Rett syndrome therapy which could be "potentially transformative" for Newron.